Robert Hopkin, MD
Clinical Genetics (M.D.) · Cincinnati, OHNPI 1447281878
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (40.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Sanofi at 48.0% of the total. Among clinical genetics (m.d.) clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 257 payments — averaging $1630.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$201K
- Amicus Therapeutics, Inc.$128K
- Chiesi USA, Inc.$59K
- Sanofi-aventis U.S. LLC$31K
- Bioverativ Therapeutics Inc.$420
- Novo Nordisk$367
- plus $25 from 2 others
Across 464 payments — averaging $5268.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amicus Therapeutics, Inc.$1.3M
- Sanofi$670K
- Sanofi US Services Inc.$267K
- Chiesi USA, Inc.$126K
- Radius Health, Inc.$42K
- Takeda Pharmaceuticals U.S.A., Inc.$29K
What the payments were for
- Consulting fees$167,44040%
- Speaking & faculty fees$146,14035%
- Travel & lodging$101,06324%
- Food & beverage$4,4321%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 148 | $201,186 |
| Amicus Therapeutics, Inc. | 65 | $127,647 |
| Chiesi USA, Inc. | 30 | $58,619 |
| Sanofi-aventis U.S. LLC | 9 | $30,811 |
| Bioverativ Therapeutics Inc. | 1 | $420 |
| Novo Nordisk | 2 | $367 |
| AstraZeneca | 1 | $24 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FABRAZYME$148,380
- GALAFOLD$90,546
- NO PRODUCT DISCUSSED$17,591
- ELFABRIO$12,740
- NEXVIAZYME$11,428
- LAMZEDE$9,067
- FERRIPROX$7,518
- DISEASE STATE$4,067
- LUMIZYME$3,305
- CERDELGA$2,048
- POMBILITI$1,324
- OPFOLDA$1,324
How this compares
$419,076 in reported general payments places this provider in the 95th percentile of 42 clinical genetics (m.d.) providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GalafoldMigalastat Hcl | 39 | $1,198,535 |
| FabrazymeAgalsidase Beta | 44 | $503,023 |
| ElfabrioPegunigalsidase Alfa-Iwxj | 12 | $444,173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amicus Therapeutics, Inc.Galafold | $127,647 | $1,198,53539 claims |
| SanofiFabrazyme | $201,186 | $503,02344 claims |
| Chiesi USA, Inc.Elfabrio | $58,619 | $444,17312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 42 clinical genetics (m.d.) providers in Ohio.
Other clinical genetics (m.d.) in Cincinnati
- Gregory GrabowskiCincinnati$123K
- Howard SaalCincinnati$121K
- Loren PenaCincinnati$38K
- Kathryn WeaverCincinnati$19K
- Nancy LeslieCincinnati$12K
- Angela SunCincinnati$3K
- Benjamin CocanougherCincinnati$1K
- Elizabeth SchorryCincinnati$1K
- Amelle ShillingtonCincinnati$977
- Ghada HijaziCincinnati$201
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.